BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22240777)

  • 1. A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C.
    Herson S; Hentati F; Rigolet A; Behin A; Romero NB; Leturcq F; Laforêt P; Maisonobe T; Amouri R; Haddad H; Audit M; Montus M; Masurier C; Gjata B; Georger C; Cheraï M; Carlier P; Hogrel JY; Herson A; Allenbach Y; Lemoine FM; Klatzmann D; Sweeney HL; Mulligan RC; Eymard B; Caizergues D; Voït T; Benveniste O
    Brain; 2012 Feb; 135(Pt 2):483-92. PubMed ID: 22240777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D.
    Rodino-Klapac LR; Lee JS; Mulligan RC; Clark KR; Mendell JR
    Neurology; 2008 Jul; 71(4):240-7. PubMed ID: 18525034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy.
    Li J; Dressman D; Tsao YP; Sakamoto A; Hoffman EP; Xiao X
    Gene Ther; 1999 Jan; 6(1):74-82. PubMed ID: 10341878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D.
    Mendell JR; Rodino-Klapac LR; Rosales XQ; Coley BD; Galloway G; Lewis S; Malik V; Shilling C; Byrne BJ; Conlon T; Campbell KJ; Bremer WG; Taylor LE; Flanigan KM; Gastier-Foster JM; Astbury C; Kota J; Sahenk Z; Walker CM; Clark KR
    Ann Neurol; 2010 Nov; 68(5):629-38. PubMed ID: 21031578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of sarcoglycans, vinculin-talin-integrin system and filamin2 in alpha- and gamma-sarcoglycanopathy: an immunohistochemical study.
    Anastasi G; Cutroneo G; Trimarchi F; Santoro G; Bruschetta D; Bramanti P; Pisani A; Favaloro A
    Int J Mol Med; 2004 Dec; 14(6):989-99. PubMed ID: 15547664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins.
    Mendell JR; Rodino-Klapac LR; Rosales-Quintero X; Kota J; Coley BD; Galloway G; Craenen JM; Lewis S; Malik V; Shilling C; Byrne BJ; Conlon T; Campbell KJ; Bremer WG; Viollet L; Walker CM; Sahenk Z; Clark KR
    Ann Neurol; 2009 Sep; 66(3):290-7. PubMed ID: 19798725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The first case of primary alpha-sarcoglycanopathy identified in Albania, in two siblings with homozygous alpha-sarcoglycan mutation.
    Babameto-Laku A; Tabaku M; Tashko V; Cikuli M; Mokini V
    Genet Couns; 2011; 22(4):377-83. PubMed ID: 22303798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant adeno-associated virus type 8-mediated extensive therapeutic gene delivery into skeletal muscle of alpha-sarcoglycan-deficient mice.
    Nishiyama A; Ampong BN; Ohshima S; Shin JH; Nakai H; Imamura M; Miyagoe-Suzuki Y; Okada T; Takeda S
    Hum Gene Ther; 2008 Jul; 19(7):719-30. PubMed ID: 18578595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient and long-term intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors.
    Li J; Wang D; Qian S; Chen Z; Zhu T; Xiao X
    Gene Ther; 2003 Oct; 10(21):1807-13. PubMed ID: 12960970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epsilon-sarcoglycan compensates for lack of alpha-sarcoglycan in a mouse model of limb-girdle muscular dystrophy.
    Imamura M; Mochizuki Y; Engvall E; Takeda S
    Hum Mol Genet; 2005 Mar; 14(6):775-83. PubMed ID: 15689353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of cardiomyopathy in delta-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors.
    Goehringer C; Rutschow D; Bauer R; Schinkel S; Weichenhan D; Bekeredjian R; Straub V; Kleinschmidt JA; Katus HA; Müller OJ
    Cardiovasc Res; 2009 Jun; 82(3):404-10. PubMed ID: 19218289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two siblings with limb-girdle muscular dystrophy type 2E responsive to deflazacort.
    Wong-Kisiel LC; Kuntz NL
    Neuromuscul Disord; 2010 Feb; 20(2):122-4. PubMed ID: 20071171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A.
    Bartoli M; Roudaut C; Martin S; Fougerousse F; Suel L; Poupiot J; Gicquel E; Noulet F; Danos O; Richard I
    Mol Ther; 2006 Feb; 13(2):250-9. PubMed ID: 16290124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies.
    Cordier L; Gao GP; Hack AA; McNally EM; Wilson JM; Chirmule N; Sweeney HL
    Hum Gene Ther; 2001 Jan; 12(2):205-15. PubMed ID: 11177557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Episodic myoglobinuria in a primary gamma-sarcoglycanopathy.
    Pena L; Kim K; Charrow J
    Neuromuscul Disord; 2010 May; 20(5):337-9. PubMed ID: 20356742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-sarcoglycanopathy (LGMD 2E) in a Spanish family.
    Rivas E; Teijeira S; dos Santos MR; Porrit I; Leturcq F; Fernandez JM; Navarro C
    Acta Myol; 2004 Dec; 23(3):159-62. PubMed ID: 15938574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer.
    Cordier L; Hack AA; Scott MO; Barton-Davis ER; Gao G; Wilson JM; McNally EM; Sweeney HL
    Mol Ther; 2000 Feb; 1(2):119-29. PubMed ID: 10933922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic correction of alpha-sarcoglycan deficiency by intra-arterial injection of a muscle-specific serotype 1 rAAV vector.
    Fougerousse F; Bartoli M; Poupiot J; Arandel L; Durand M; Guerchet N; Gicquel E; Danos O; Richard I
    Mol Ther; 2007 Jan; 15(1):53-61. PubMed ID: 17164775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The frequency of patients with adhalin deficiency in a muscular dystrophy patient population].
    Hayashi YK; Arahata K
    Nihon Rinsho; 1997 Dec; 55(12):3165-8. PubMed ID: 9436429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcoglycanopathies: can muscle immunoanalysis predict the genotype?
    Klinge L; Dekomien G; Aboumousa A; Charlton R; Epplen JT; Barresi R; Bushby K; Straub V
    Neuromuscul Disord; 2008 Dec; 18(12):934-41. PubMed ID: 18996010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.